Tag: MDS

Pytorch_all_l Benchmarks – OpenBenchmarking.org

AMD Ryzen 9 5900X 12-Core testing with a ASUS TUF GAMING B550M-PLUS (WI-FI) (1801 BIOS) and MSI NVIDIA GeForce RTX 3080 10GB on Ubuntu 22.04 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2312292-NE-PYTORCHAL51…

Continue Reading Pytorch_all_l Benchmarks – OpenBenchmarking.org

UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Faculty and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) joined the world’s largest hematology community to discuss the latest updates in blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held December 9-12, 2023 in San Diego and online. At the meeting,…

Continue Reading UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Study uncovers unique genetic diversity in Australian Indigenous populations

Scientists at the Australian National University (ANU) have comprehensively analyzed the genomes of Australian Indigenous communities and found a rich genetic diversity. Their study is published in the journal Nature. Study: Indigenous Australian genomes show deep structure and rich novel variation. Image Credit: ChameleonsEye / Shutterstock Background Genetic structures of Australian Indigenous…

Continue Reading Study uncovers unique genetic diversity in Australian Indigenous populations

Indigenous Australian genomes show deep structure and rich novel variation

Inclusion and ethics The DNA samples analysed in this project form part of a collection of biospecimens, including historically collected samples, maintained under Indigenous governance by the NCIG11 at the John Curtin School of Medical Research at the Australian National University (ANU). NCIG, a statutory body within ANU, was founded…

Continue Reading Indigenous Australian genomes show deep structure and rich novel variation

FibroGen (FGEN) Presents Data from Phase 3 MATTERHORN Trial of Roxadustat

FibroGen, Inc. (NASDAQ: FGEN) announced today the presentation of efficacy and safety data from MATTERHORN, a Phase 3 clinical study of roxadustat for the treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held…

Continue Reading FibroGen (FGEN) Presents Data from Phase 3 MATTERHORN Trial of Roxadustat

Bristol-Myers Squibb (BMY) Reports Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl

Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS) (Oral Presentation #193) who may require red blood cell (RBC)…

Continue Reading Bristol-Myers Squibb (BMY) Reports Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Continue Reading Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

FibroGen Presents Data from Phase 3 MATTERHORN Trial of

A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047ǂ). Dr. Moshe Mittelman’s presentation was selected for the “2024 Highlights of ASH” SAN FRANCISCO, Dec. 09, 2023 (GLOBE…

Continue Reading FibroGen Presents Data from Phase 3 MATTERHORN Trial of

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed, Refractory Myelofibrosis -December 07, 2023 at 07:35 am EST

FOSTER CITY – Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF). ‘Reaching fifty percent enrollment in IMpactMF…

Continue Reading Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed, Refractory Myelofibrosis -December 07, 2023 at 07:35 am EST

Phase 3 trial of buntanetap for early-stage Parkinson’s nears end

Annovis Bio has announced the last patient completed the final visit in its Phase 3 clinical trial testing buntanetap for people with with early-stage Parkinson’s disease. Since the study was initiated in August 2022, more than 616 patients were screened, 523 enrolled, and 471 completed the study across 67 sites…

Continue Reading Phase 3 trial of buntanetap for early-stage Parkinson’s nears end

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

IMpactMF is the first and only Phase 3 clinical trial to evaluate overall survival as the primary endpoint in R/R MF An interim analysis is expected in the first half of 2025, with a final analysis expected in the first half of 2026 FOSTER CITY, Calif., December 06, 2023–(BUSINESS WIRE)–Geron…

Continue Reading Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Circular RNA Associated With Higher Risk and Poor Outcomes in MDS and AML

The circular RNA (circRNA) circZBTB46 was expressed at increasing levels among patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and was associated with shorter survival, according to the results of a study published in the journal Clinical and Experimental Medicine. A type of noncoding, stable RNA,…

Continue Reading Circular RNA Associated With Higher Risk and Poor Outcomes in MDS and AML

Phase 3 Results Add to Hope for Patients With Myelodysplastic Syndromes < Yale School of Medicine

For people living with certain blood cancers, including lower-risk myelodysplastic syndromes (LR-MDS), there are limited effective treatment options. This is especially true for MDS patients who are red blood cell transfusion-dependent (RBC-TD) and who do not respond to, or are not eligible for, the treatment typically used to stimulate bone-marrow…

Continue Reading Phase 3 Results Add to Hope for Patients With Myelodysplastic Syndromes < Yale School of Medicine

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS -December 04, 2023 at 05:00 am EST

Geron Corporation announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will be available in print at a later date….

Continue Reading Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS -December 04, 2023 at 05:00 am EST

Geron Corp (GERN) Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will…

Continue Reading Geron Corp (GERN) Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.–(BUSINESS WIRE)– Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is…

Continue Reading Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609(7926):354–60. Article  CAS  PubMed  PubMed Central  Google Scholar  Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, et al. Dapl1 controls NFATc2…

Continue Reading Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Ryvu Therapeutics Reports Third Quarter 2023 Financial

The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022. Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of Hematology (ASH) Annual Meeting in December. Preparations for executing Phase II clinical trials of RVU120 in…

Continue Reading Ryvu Therapeutics Reports Third Quarter 2023 Financial

DNA methylation change in blood cells of FB and CFS patients

Introduction Fibromyalgia (FM) and Chronic Fatigue Syndrome (CFS) are characterized by chronic pain, fatigue, and weakness. Patients with these symptoms also suffer from sleep abnormalities and report affected cognitive processes such as memory. The diagnosis of these two syndromes is challenging and is based on questionnaires that make the diagnosis…

Continue Reading DNA methylation change in blood cells of FB and CFS patients

Serial Next Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to a prostate cancer course. Dr. Alan Bryce provided an overview of the use and application of serial next generation sequencing (NGS) in the castrate-resistant prostate cancer disease…

Continue Reading Serial Next Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024

Bug in element-wise multiplication of `torch.sparse_csr_tensor`s on GPU – 0’s in result considered significant

🐛 Describe the bug Problem:The problem occurs when using the PyTorch version 2.1.1. The result of element-wise multiplication between two torch.sparse_csr_tensors consider 0s as significant values and retain them in their sparse form. This is not the expected behavior. Moreover, this bug occurs only when the operation is run on…

Continue Reading Bug in element-wise multiplication of `torch.sparse_csr_tensor`s on GPU – 0’s in result considered significant

Analyzing somatic mutations by single-cell whole-genome sequencing

Failla, G. The aging process and cancerogenesis. Ann. N. Y. Acad. Sci. 71, 1124–1140 (1958). Article  CAS  PubMed  Google Scholar  Szilard, L. On the nature of the aging process. Proc. Natl Acad. Sci. USA 45, 30–45 (1959). Article  CAS  PubMed  PubMed Central  Google Scholar  Vijg, J. & Dong, X. Pathogenic…

Continue Reading Analyzing somatic mutations by single-cell whole-genome sequencing

Using Genomic Profiling to Provide Personalized Medicine in MDS

Myelodysplastic syndromes (MDS) is a group of clonal hematopoietic neoplasms characterized by the combination of persistent unexplained cytopenia (or cytopenias) and morphologic dysplasia and a propensity to progress to bone marrow failure or acute myeloid leukemia (AML).1 The treatment landscape for MDS is continually progressing and involves a multidisciplinary approach…

Continue Reading Using Genomic Profiling to Provide Personalized Medicine in MDS

Comparative genomics and genome-wide SNPs of endangered Eld’s deer provide breeder selection for inbreeding avoidance

De novo genome assemblies and genome annotation We assembled a de novo genome of a seven-year-old male SED from Ubon Ratchathani Zoo using a combination of Illumina short-reads (92.94 × coverage) and PacBio long-reads (61.6 × coverage) (GenBank accession number: JACCHN000000000). Additionally, we used MGI short-reads (52.15 × coverage) to assemble a de novo genome of…

Continue Reading Comparative genomics and genome-wide SNPs of endangered Eld’s deer provide breeder selection for inbreeding avoidance

Two sympatric lineages of Australian Cnestus solidus share Ambrosiella symbionts but not Wolbachia

Andersen HF, Jordal BH, Kambestad M, Kirkendall LR (2012) Improbable but true: the invasive inbreeding ambrosia beetle Xylosandrus morigerus has generalist genotypes. Ecol Evol 2:247–257 Article  PubMed  PubMed Central  Google Scholar  Arif S, Gerth M, Hone‐Millard WG, Nunes MDS, Dapporto L, Shreeve TG (2021) Evidence for multiple colonisations and Wolbachia…

Continue Reading Two sympatric lineages of Australian Cnestus solidus share Ambrosiella symbionts but not Wolbachia

Targeting nucleic acid phase transitions as a mechanism of action for antimicrobial peptides

Phase separation propensity of AMPs We retrieved the sequences of previously identified AMPs deposited into the Database of Antimicrobial Activity and Structure of Peptides (DBAASP)40 and in the APD3 antimicrobial peptide database41 to analyse their predicted propensities to undergo phase separation. Interestingly, we find that some AMPs possess features42,43,44 that…

Continue Reading Targeting nucleic acid phase transitions as a mechanism of action for antimicrobial peptides

Phase 3 trials of tavapadon for Parkinson’s motor symptoms near end

An ongoing and global Phase 3 clinical trial program for oral tavapadon, a selective dopamine receptor agonist aiming to improve motor function in people with Parkinson’s disease, expects to release study findings next year. Three separate, 27-week trials are evaluating tavapadon’s efficacy, safety, and tolerability against a placebo in recently…

Continue Reading Phase 3 trials of tavapadon for Parkinson’s motor symptoms near end

Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis

Identification of CH cases from WGS in ISL and UKB We used WGS from 45,510 Icelanders and 130,709 British ancestry participants from the UKB17,18. Average sequencing depth was 33× for UKB and 38× for ISL. Participants with prior diagnoses of hematological disorders or grossly abnormal hematology measurements on entry were…

Continue Reading Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis

Geron Corporation Eyes $3.5 Billion Opportunity in MDS and MF Treatment Market By Investing.com

© Reuters. Geron (NASDAQ:) Corporation (NASDAQ:GERN) has updated its progress and plans during its third quarter 2023 earnings conference call, highlighting the potential of its drug imetelstat for the treatment of lower-risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). The company has submitted a New Drug Application (NDA) for imetelstat, which…

Continue Reading Geron Corporation Eyes $3.5 Billion Opportunity in MDS and MF Treatment Market By Investing.com

Karyopharm Therapeutics Reports Q3 2023 Financial Results, Highlights Strong Position for Growth By Investing.com

© Reuters. Karyopharm Therapeutics (NASDAQ: NASDAQ:) has reported its financial results for the third quarter of 2023, noting a strong position for growth backed by its pipeline of innovative oral selective inhibitors and nuclear export. The company expects total revenues of $145 million to $160 million in 2023, and anticipates…

Continue Reading Karyopharm Therapeutics Reports Q3 2023 Financial Results, Highlights Strong Position for Growth By Investing.com

Genes | Free Full-Text | Unraveling the Genetic Threads of History: mtDNA HVS-I Analysis Reveals the Ancient Past of the Aburra Valley

1. Introduction The Antioquia region has played a pivotal role in the pre-Hispanic history of South America, serving as a gateway for the initial human migrations to the continent and as a hub for the development of a sophisticated culture deeply rooted in the utilization of natural resources and advanced…

Continue Reading Genes | Free Full-Text | Unraveling the Genetic Threads of History: mtDNA HVS-I Analysis Reveals the Ancient Past of the Aburra Valley

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS). Four abstracts have been accepted for presentation at the 65th…

Continue Reading Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS | Business

FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov 2, 2023– Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS). Four abstracts have been accepted for presentation…

Continue Reading Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS | Business

2023-11-02 | NDAQ:AGIO | Press Release

– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK Deficiency; ACTIVATE-Kids Study Achieves >50% Enrollment – – On Track for Data Readouts in Two Phase…

Continue Reading 2023-11-02 | NDAQ:AGIO | Press Release

Agios Reports Business Highlights and Third Quarter 2023

– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK Deficiency; ACTIVATE-Kids Study Achieves >50% Enrollment – – On Track for Data Readouts in Two Phase 3 Trials…

Continue Reading Agios Reports Business Highlights and Third Quarter 2023

Is pediatric SAMD9 germline mutation myelodysplastic syndrome always associated with gain of function mutation?

Pediatric SAMD9 germline mutation myelodysplastic syndrome (MDS) is not always associated with gain-of-function mutations. In fact, the germline SAMD9/9L mutations can be loss-of-function mutations. These mutations have been found in pediatric MDS patients with monosomy 7, a poor prognostic factor. The prevalence of SAMD9/9L mutations in pediatric MDS is around…

Continue Reading Is pediatric SAMD9 germline mutation myelodysplastic syndrome always associated with gain of function mutation?

Discovery unlocks potential new arsenal to target leukemia and other cancers

Integrative analysis of samples from patients with AML. a, Unsupervised hierarchical clustering analysis on the expression of 300 transcripts with the greatest variance-to-mean ratios among 30 individual AMLs from our repository that can successfully generate AML PDX. MLD, multi-lineage dysplasia; MDS, myelodysplastic syndromes; MLL, mixed-lineage leukemia; NOS, not otherwise specified….

Continue Reading Discovery unlocks potential new arsenal to target leukemia and other cancers

MtDNA variation, oxygen and nutrient sensing pathways in the penetrance of mitochondrial disease

  [eng] Mitochondrial diseases (MDs) are metabolic rare disorders impairing the OXPHOS system. mtDNA is polyplasmic, therefore mutant and wild-type alleles can coexist in the same mitochondria or cell in a state known as heteroplasmy. The regulation of heteroplasmy is poorly understood and some nutrient sensing pathways seem to have…

Continue Reading MtDNA variation, oxygen and nutrient sensing pathways in the penetrance of mitochondrial disease

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153 (1984). Article  CAS  PubMed  Google Scholar  Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains….

Continue Reading T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Personalis start early access program for cancer detection blood test

NeXT Personal Dx has a specificity exceeding 99.9% and can detect down to 1×10-⁶ tumour fraction. Credit: ArtemisDiana / Shutterstock. Personalis has launched the Early Access Program for NeXT Personal Dx, a liquid biopsy laboratory-developed test for detecting molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is…

Continue Reading Personalis start early access program for cancer detection blood test

New Notification out, Check Post, Age, Salary, and Interview Details

National Centre For Cell Science Recruitment 2023: New Notification out, Check Post, Age, Salary, and Interview Details National Centre for Cell Science Recruitment 2023: The National Centre for Cell Science (NCCS), an autonomous institution of the Department of Biotechnology, Ministry of Science and Technology, Government of India, is inviting applications…

Continue Reading New Notification out, Check Post, Age, Salary, and Interview Details

Bioconductor – GloScope (development version)

DOI: 10.18129/B9.bioc.GloScope   This is the development version of GloScope; to use it, please install the devel version of Bioconductor. Population-level Representation on scRNA-Seq data Bioconductor version: Development (3.18) This package aims at representing and summarizing the entire single-cell profile of a sample. It allows researchers to perform important bioinformatic…

Continue Reading Bioconductor – GloScope (development version)

New thesis on prognostication for patients with myelodysplastic syndrome

Credit: Pixabay/CC0 Public Domain Maria Creignou from the Hematology Unit (HERM) at the Department of Medicine, Huddinge (MedH) is defending her thesis: “Improving prognostication for patients with myelodysplastic syndromes” on 27 October 2023. Her main supervisor is Professor Eva Hellström Lindberg (MedH). What is the main focus of your thesis?…

Continue Reading New thesis on prognostication for patients with myelodysplastic syndrome

Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone

Niraparib and abiraterone acetate plus prednisone combination therapy also showed clinically relevant improvement versus standard of care in time to symptomatic progression and time to cytotoxic chemotherapy MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis (FA) of…

Continue Reading Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone

Amylyx Pharmaceuticals hopes to launch largest PSP trial to date

The company announced on Thursday (October 19) that it has an upcoming presentation on the design of a phase 3 clinical trial of a drug called AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) in PSP. The presentation will be given at Neuro 2023 and CBD International Research Symposium. “We designed ORION…

Continue Reading Amylyx Pharmaceuticals hopes to launch largest PSP trial to date

Can golden retrievers live longer? Researchers find gene associated with longevity in the breed

UC Davis researchers have found a gene associated with longevity in Golden Retrievers, one of the most popular breeds of dogs. Credit: Jessica Hecock, UC Davis Golden retrievers are one of the most popular breeds of dogs. But research shows they have up to a 65% chance of dying from…

Continue Reading Can golden retrievers live longer? Researchers find gene associated with longevity in the breed

Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson’s disease

. 2023 Oct 18;13(1):17796. doi: 10.1038/s41598-023-45078-3. Affiliations Expand Affiliations 1 Department of Pathology, Stanford University School of Medicine, 300 Pasteur Dr., R271/217, Stanford, CA, 94305, USA. 2 Department of Biological Sciences, San Jose State University, San Jose, CA, 95192, USA. 3 Department of Experimental Medical Science, Lund University, Lund, Sweden….

Continue Reading Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson’s disease

Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium -October 19, 2023 at 09:00 am EDT

Amylyx Pharmaceuticals, Inc. announced an upcoming presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) in progressive supranuclear palsy (PSP). Neuro2023: The PSP and CBD International Research Symposium will take place on October 19, 2023 to October…

Continue Reading Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium -October 19, 2023 at 09:00 am EDT

Mexican Biobank advances population and medical genomics of diverse ancestries

Encuesta Nacional de Salud 2000 Since 1988, Mexico has established periodical National Health Surveys (Encuesta Nacional de Salud (ENSA), originally conceived as National Nutrition Surveys) for surveillance of Mexican population-based nutrition and health metrics. In this study, we use data and samples collected from the survey carried out in 2000,…

Continue Reading Mexican Biobank advances population and medical genomics of diverse ancestries

Check Post, Qualification, Age, Salary, Vacancies, Selection Process and How to Apply

NCCS Recruitment 2023: Check Post, Qualification, Age, Salary, Vacancies, Selection Process and How to Apply NCCS Recruitment 2023:  The National Centre for Cell Science (NCCS) is accepting applications for the posts of Research Associate – I, Project Associate – II, Senior Research Fellow, Junior Research Fellow and Project Associate –…

Continue Reading Check Post, Qualification, Age, Salary, Vacancies, Selection Process and How to Apply

New Notificaction, Check Vacancies, Post, Age, Salary, Qualification and Other Vital Details

NCCS Recruitment 2023: Check Vacancies, Post, Age, Salary, Qualification and Other Vital Details NCCS Recruitment 2023: The National Centre for Cell Science (NCCS) is hiring eligible and experienced candidates for the post of Research Associate – I, Project Associate – II, Senior Research Fellow, Junior Research Fellow and Project Associate…

Continue Reading New Notificaction, Check Vacancies, Post, Age, Salary, Qualification and Other Vital Details

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor types FHD-286, a potent, selective inhibitor of BRG1 and BRM, shows potential as a broad-based differentiation agent in both clinical and pre-clinical studies in multiple tumor types CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq:…

Continue Reading Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

Gilead Discontinues Phase 3 ENHANCE-2 Trial | Image Credit: ©freshidea – stock.adobe.com The phase 3 ENHANCE-2 trial (NCT04778397) examining the frontline combination of magrolimab and azacitidine (Vidaza) vs physician’s choice of venetoclax (Venclexta) with azacitidine or intensive chemotherapy in patients with acute myeloid leukemia and TP53 mutations has been discontinued,…

Continue Reading Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

Complex multifactorial DE analysis with limma/edgeR based on rnaseq data

Dear Biostars, I would like to ask you one specific question regarding the DE analysis on an RNASeq dataset of samples, spanning a multi-factor experimental design. Briefly, unstimulated neutrophils of 4 healthy donors, were cultivated with distinct treatment conditions-that is, supernatant of organoids from different cancer/normal patient samples; There are…

Continue Reading Complex multifactorial DE analysis with limma/edgeR based on rnaseq data

Pemmaraju Discusses Development of Targeted Therapy for BPDCN

Naveen Pemmaraju, MD Associate Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX CASE SUMMARY A man aged 67 years was referred from a dermatologist. Referred initially to dermatologist for progressive, persistent, cutaneous nodules that patient first noticed 3 weeks prior…

Continue Reading Pemmaraju Discusses Development of Targeted Therapy for BPDCN

Naturalistic Experimental Setup for Studying Real-World Human Actions

To begin, open the experiment software on the experiment PC and run the experiment script 1 dot M script. Enter the participant ID and age. Then the script initiates the experiment, displaying a cross at the center of the participant display and a warning about pressing escape button to start…

Continue Reading Naturalistic Experimental Setup for Studying Real-World Human Actions

Zeidan Recaps the Phase 3 IMerge Trial of Imetelstat in Lower-Risk MDS

Amer Zeidan, MBBS, Yale Cancer Center, discusses the rationale of studying imetelstat in the phase 3 IMerge trial (NCT02598661) in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome (MDS) that is relapsed or refractory to erythropoiesis stimulating agents. According to results from the study, response rates with imetelstat were…

Continue Reading Zeidan Recaps the Phase 3 IMerge Trial of Imetelstat in Lower-Risk MDS

Diagnostic genome sequencing improves diagnostic yield: a prospective single-centre study in 1000 patients with inherited eye diseases

Introduction Although protein-coding regions represent only 1–2% of the human genome, they harbour an estimated 85% of annotated pathogenic variants.1 2 Despite these numbers, genome sequencing (GS) usually achieves a higher diagnostic yield than sequencing approaches that focus on exonic regions, not least because of its more homogeneous coverage3 4…

Continue Reading Diagnostic genome sequencing improves diagnostic yield: a prospective single-centre study in 1000 patients with inherited eye diseases

Key Details of Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy: Gunter Hoglinger, MD

WATCH TIME: 4 minutes “The most important aspects when choosing patients for this trial is to have specificity for the underlying neurobiology. We know that possible and probably patients with Richardson syndrome, as diagnosed by the MDS criteria, have a high specificity of more than 90% to have an underlying…

Continue Reading Key Details of Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy: Gunter Hoglinger, MD

10/24/2023 M-I Dept. Seminar / SAMD9-Mediated Innate Immunity Against Viruses and Myeloid Tumors

When: Tuesday, October 24, 202312:00 PM – 1:00 PM CT Where: Simpson Querrey Biomedical Research Center, SQ Auditorium, 303 E. Superior Street, Chicago, IL 60611 map it Audience: Faculty/Staff – Post Docs/Docs – Graduate Students Contact: Cynthia Naugles   (312) 503-0489 Group: Department of Microbiology-Immunology Seminars/Events Category: Lectures & Meetings Description:…

Continue Reading 10/24/2023 M-I Dept. Seminar / SAMD9-Mediated Innate Immunity Against Viruses and Myeloid Tumors

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

Data from ongoing phase 3 clinical trials could continue to alter the treatment landscape for patients with lower-risk myelodysplastic neoplasms (MDS), according to Uwe Platzbecker, MD. In an interview with OncLive®, Platzbecker, a professor of hematology and director of Medical Clinic I at the University Hospital of Leipzig in Germany,…

Continue Reading Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

A fungal sesquiterpene biosynthesis gene cluster critical for mutualist-pathogen transition in Colletotrichum tofieldiae

A Ct strain severely inhibits plant growth in a nutrient-dependent manner A Ct strain, Ct61, isolated from a wild A. thaliana population in Spain, promotes plant growth under low Pi conditions by transferring phosphorus to the host3. In addition to Ct61, five different Ct strains have been isolated from various…

Continue Reading A fungal sesquiterpene biosynthesis gene cluster critical for mutualist-pathogen transition in Colletotrichum tofieldiae

Geron to Participate in the Baird 2023 Global Healthcare Conference

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Baird 2023 Global Healthcare Conference in New York City, NY, on Tuesday, September 12, 2023, at…

Continue Reading Geron to Participate in the Baird 2023 Global Healthcare Conference

Phase 3 KINECT-4 Findings Show Valbenazine Decreases Tardive Dyskinesia Severity

Recently, an analysis of the phase 3 KINECT-4 trial (NCT02405091) showed a comparable pattern of improvement in clinician-rated tardive dyskinesia (TD) severity and awareness/distress and patient-reported TD impact over 48 weeks with valbenazine (Ingrezza, Neurocrine Biosciences).1 Assessed through the Abnormal Involuntary Movement Scale (AIMS) and the Trajectories of Tardive Dyskinesia…

Continue Reading Phase 3 KINECT-4 Findings Show Valbenazine Decreases Tardive Dyskinesia Severity

linear variable not recognised

Hi,  I’m woreking with some linear variables, normally all is fine, but I don’t konw why PLINK doesn’t recognise as linears the variables I introduced today.   With these variables and this command it works:  Meas119.87 18.07 10.54 23.46 7.36 30.31 …

Continue Reading linear variable not recognised

I-Mab’s Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says -Today at 06:11 am| MarketScreener

I-Mab is a China-based company mainly engaged in the development of innovative global biotechnology. The Company’s main businesses include engaging in track record in innovation, developing innovative drug candidates and conduct clinical validation of the assets and commercialization. The Company’s pipeline is composed of ten clinical-stage assets and ten preclinical…

Continue Reading I-Mab’s Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says -Today at 06:11 am| MarketScreener

Allogeneic HCT Improves Survival Rates for TP53-Mutated MDS

This article was originally published by Targeted Oncology. This version has been edited. Allogeneic hematopoietic cell transplantation (HCT) improved overall survival (OS) vs non-HCT treatment in patients with myelodysplastic syndrome (MDS) harboring TP53 mutations.1 The findings come from a study performed at Dana-Farber Cancer Institute and published in the Journal…

Continue Reading Allogeneic HCT Improves Survival Rates for TP53-Mutated MDS

Reblozyl Approved as First-Line Treatment for Anemia in Lower-Risk Myelodysplastic Syndromes

The Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) as first-line treatment of anemia in adults with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions and are erythropoiesis stimulating agent (ESA)-naïve. The approval was based on interim results from the pivotal…

Continue Reading Reblozyl Approved as First-Line Treatment for Anemia in Lower-Risk Myelodysplastic Syndromes

Read data file and produce RPKM in edgeR

This post is in response to a number of emails and posts asking about reading data into edgeR and producing RPKM. Suppose we start with a tab-delimited file counts.txt like this: To read this into edgeR: library(edgeR) Data <- read.delim(“counts.txt”, sep=”\t”, row.names=1) y <- DGEList(Data, annotation=”Length”) To normalize the library…

Continue Reading Read data file and produce RPKM in edgeR

Multiparameter prediction of myeloid neoplasia risk

Data acquisition UKB is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants. UKB has approval from the North West Multicentre Research Ethics Committee (11/NW/0382) and all participants provided written informed consent. The present study has been conducted under approved…

Continue Reading Multiparameter prediction of myeloid neoplasia risk

PARP14 correlates with GBM proliferation and poor prognosis by elevating expression of SAMD/SAMD9L

Jacob F, Salinas RD, Zhang DY et al (2020) A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180(1):188–204 e122. doi.org/10.1016/j.cell.2019.11.036 Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251….

Continue Reading PARP14 correlates with GBM proliferation and poor prognosis by elevating expression of SAMD/SAMD9L

Reference LINE-1 insertion polymorphisms correlate with Parkinson’s disease progression and differential transcript expression in the PPMI cohort

Raiz, J. et al. The non-autonomous retrotransposon SVA is trans -mobilized by the human LINE-1 protein machinery. Nucl. Acids Res. 40, 1666–1683 (2012). Article  CAS  PubMed  Google Scholar  Kim, S., Cho, C.-S., Han, K. & Lee, J. Structural variation of Alu element and human disease. Genom. Inform. 14, 70 (2016)….

Continue Reading Reference LINE-1 insertion polymorphisms correlate with Parkinson’s disease progression and differential transcript expression in the PPMI cohort

High-Risk MDS Patients May Benefit from Allogenic Transplants

Study Title: Allogeneic Hematopoietic Cell Transplantation Improves Outcome in MDS across High-Risk genetic subgroups: Genetic analysis of the BMT CTN 1102 study Publication: Journal of Clinical Oncology, Click here for link Dana-Farber Authors: Jurjen Versluis, MD; Christopher J. Gibson, MD; Corey Cutler, MD, MPH, FRCPC; R. Coleman Lindsley, MD, PhD…

Continue Reading High-Risk MDS Patients May Benefit from Allogenic Transplants

US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment

The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk myelodysplastic syndromes Representational image Gilead Sciences announced that the US Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in US studies evaluating magrolimab…

Continue Reading US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS | Small Molecules

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS Details Category: Small Molecules Published on Tuesday, 22 August 2023 11:00 Hits: 268 FOSTER CITY, CA, USA I August 21, 2023 I Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced…

Continue Reading Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS | Small Molecules

Inter-comparison of marine microbiome sampling protocols

Environmental communities For the MetaB16SV4V5 sequencing results (n = 60), we initially obtained between 714,103 and 2,841,890 raw reads per sample (median = 1,462,584 reads, IQR = 267,472 reads). The final number of high quality reads attributed to taxonomic lineages ranged between 169,945 and 1,517,860 reads per sample (median = 660 878 reads, IQR = 438 932 reads). Thus, between…

Continue Reading Inter-comparison of marine microbiome sampling protocols

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

Raajit K. Rampal, MD, PhD Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents (HMAs) can lead to spleen and symptom burden reductions, according to Raajit K. Rampal, MD,…

Continue Reading Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

WISE-SCOPE Fellowship Program By DST

WISE-SCOPE Fellowship Program By DST – Opportunity For Women Scientists & Technologists WISE-SCOPE Fellowship Program By DST – Opportunity For Women Scientists & Technologists. The WISE SCOPE Fellowship program of the Department of Science & Technology (DST) aims to provide opportunity to Women Scientists and Technologists who have completed Ph.D….

Continue Reading WISE-SCOPE Fellowship Program By DST

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

Submitted U.S. New Drug Application in lower risk MDS in June 2023 Additional data and analyses from IMerge Phase 3 presented at medical meetings further strengthen value proposition and differentiation of imetelstat Potential U.S. commercial launch in lower risk MDS expected in first half of 2024 FOSTER CITY, Calif.–(BUSINESS WIRE)–…

Continue Reading Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

Agios Announces Exclusive Worldwide License Agreement for

– Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios’ Scientific Expertise and Capabilities in Rare Hematologic Diseases with Alnylam’s Industry-Leading siRNA Platform – – Alnylam to Receive a $17.5 million Upfront Payment and is Eligible to Receive Potential Future Development and…

Continue Reading Agios Announces Exclusive Worldwide License Agreement for

A diverse ancestrally-matched reference panel increases genotype imputation accuracy in a underrepresented population

In the present study, we enrolled 412 participants from the Southeast Asian Brugada syndrome cohort (ClinicalTrials.gov number, NCT04232787). The study was approved by the Institutional Review Board (IRB) of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (IRB No. 431/58). All methods were performed in accordance with relevant guidelines/regulations. Informed…

Continue Reading A diverse ancestrally-matched reference panel increases genotype imputation accuracy in a underrepresented population

Trial Evaluating Magrolimab Plus Azacitidine in Higher-Risk MDS Discontinued

Gilead has decided to discontinue the phase 3 ENHANCE study evaluating magrolimab plus azacitidine for the first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS). Magrolimab is an investigational monoclonal antibody that binds to CD47 and blocks the inhibitory CD47-signal regulatory protein (SIRPα) interaction. This enhances the ability of macrophages…

Continue Reading Trial Evaluating Magrolimab Plus Azacitidine in Higher-Risk MDS Discontinued

Annual Clinical Update on MDS Sees Hope in Precision Medicine, Use of Oral Therapy

The Annual Clinical Update in Hematological Malignancies, appearing online in early June and now publishing in the August issue of the American Journal of Hematology (AJH), includes an update on myelodysplastic syndromes by Guillermo Garcia-Manero, MD, who leads the MDS Section in the Department of Leukemia at The University of…

Continue Reading Annual Clinical Update on MDS Sees Hope in Precision Medicine, Use of Oral Therapy

Gilead Discontinues Phase 3 ENHANCE Trial in Higher-Risk MDS

Gilead Discontinues Phase 3 ENHANCE Trial in Higher-Risk MDS Gilead has announced that the phase 3 ENHANCE trial (NCT04313881), which was investigating frontline magrolimab and azacitidine (Vidaza) vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome (MDS), will no longer be continuing. The company cited futility as the reason…

Continue Reading Gilead Discontinues Phase 3 ENHANCE Trial in Higher-Risk MDS

pyGROMODS: a Python package for the generation of input files for molecular dynamic simulation with GROMACS

The pyGROMODS, an easy-to-use cross-platform python-based package, with a graphical user interface, for the generation of molecular dynamic (MD) input files and running MD simulation (MDS) of proteins, peptides, and protein-ligand complex using GROMACS, is here presented. Four routes, with underlining Python scripts, are implemented in pyGROMODS for the generation…

Continue Reading pyGROMODS: a Python package for the generation of input files for molecular dynamic simulation with GROMACS

Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS

The phase 3 ENHANCE trial (NCT04313881) evaluating the first-line combination of magrolimab and azacitidine (Vidaza) vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome (MDS) has been discontinued due to futility at a planned analysis, according to an announcement from Gilead Sciences.1 Trial investigators and the company are evaluating…

Continue Reading Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS

Gilead Sciences (GILD) To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in…

Continue Reading Gilead Sciences (GILD) To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population….

Continue Reading Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in…

Continue Reading Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS

Rami Komrokji, MD, vice chair, Malignant Hematology Department, head, the Leukemia and MDS Section, Moffitt Cancer Center, senior member, the Malignant Hematology and Experimental Therapeutics Program, professor in Medicine & Oncologic Sciences, the College of Medicine, the University of South Florida, shares the potential clinical implications of data from the…

Continue Reading Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS

SETBP1 is dispensable for normal and malignant hematopoiesis

Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2010;115:615–25. Article  CAS  PubMed  Google Scholar  Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno…

Continue Reading SETBP1 is dispensable for normal and malignant hematopoiesis

PLSCR1 identified as a potent anti-SARS-CoV-2 factor in COVID-19 immunity

In a recent study published in Nature, researchers identified the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) function of phospholipid scramblase 1 (PLSCR1), a cell-autonomous restriction factor induced by interferon-gamma (IFNγ). Its identification will help enhance the understanding of protective immunity in the human IFN response. The study used genome-wide…

Continue Reading PLSCR1 identified as a potent anti-SARS-CoV-2 factor in COVID-19 immunity

Associate Professor in Genetics and Bioinformatics

Location: University of Birmingham, Edgbaston, Birmingham UK. Full time starting salary is normally in the range £54,421 to £63,059, with potential progression once in post to £82,225 (Grade 9). Full Time, Fixed Term maternity cover contract up to December 2024. Closing date: 10th August 2023 The School of Biosciences invites…

Continue Reading Associate Professor in Genetics and Bioinformatics

Pfizer kicks $25M into CellCentric

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25m to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer.  Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in…

Continue Reading Pfizer kicks $25M into CellCentric

Researcher job with St. Jude Children’s Research Hospital (St. Jude)

The Obeng Laboratory is part of the Department of Oncology at St. Jude Children’s Research Hospital in Memphis, TN. Research in the Obeng lab centers on the pathogenesis of myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). We are investigating how acquired somatic mutations in hematopoietic stem cells lead to…

Continue Reading Researcher job with St. Jude Children’s Research Hospital (St. Jude)

Fluorescence lifetime FRET assay for live-cell high-throughput screening of the cardiac SERCA pump yields multiple classes of small-molecule allosteric modulators

Molecular biology A two-color intramolecular human SERCA2a (2CS) biosensor, based on human cardiac SERCA2a fused to green fluorescent protein (eGFP) and red fluorescent protein (tagRFP) was developed to detect structural changes that are related to the functional changes of SERCA20,22,25. Briefly, tagRFP was genetically fused to the N-terminus of SERCA…

Continue Reading Fluorescence lifetime FRET assay for live-cell high-throughput screening of the cardiac SERCA pump yields multiple classes of small-molecule allosteric modulators

Orphan Drug Designation for CellCentric multiple myeloma drug

CellCentric, a UK-based biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib in the treatment of multiple myeloma.  Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring.  It is a first-in-class drug, with a…

Continue Reading Orphan Drug Designation for CellCentric multiple myeloma drug

JCM | Free Full-Text | Reduction of EpCAM-Positive Cells from a Cell Salvage Product Is Achieved by Leucocyte Depletion Filters Alone

1. Introduction Allogeneic blood transfusion is potentially life-saving for bleeding patients, but it is not totally risk-free [1]. Intraoperative cell salvage, also known as autotransfusion, is a strategy designed to reduce the need for allogeneic transfusions. This procedure involves the collection of patient blood from the surgical field, which is…

Continue Reading JCM | Free Full-Text | Reduction of EpCAM-Positive Cells from a Cell Salvage Product Is Achieved by Leucocyte Depletion Filters Alone

Examining TET2/ASXL1 and Core Mutations DNA Methylation Profile in MDS

The following is a summary of “Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome,” published in the June 2023 issue of Hematology by Feng, et al. For a study on myelodysplastic syndromes (MDS), researchers sought to analyze genetic mutations and clinical characteristics and examine their…

Continue Reading Examining TET2/ASXL1 and Core Mutations DNA Methylation Profile in MDS

Research Suggests Diagnostic Evaluation May Be of Little Value to Older Patients With MDS

Demographic and clinical disparities exist in the accurate diagnosis of older patients with myelodysplastic syndromes (MDS), according to new research published in The Oncologist. Investigators also found receipt of diagnostic evaluation (DE) influenced subsequent treatment in these patients, but not survival, suggesting the process may be considered low-value care. “Older…

Continue Reading Research Suggests Diagnostic Evaluation May Be of Little Value to Older Patients With MDS